---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-059077"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T12:57:00.205418+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO

## Summary
- Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.
- CFO Scott Giacobello appointed Interim CEO and President effective March 15, 2023, while retaining CFO role.
- Founder Neil Desai, Ph.D., continues as Executive Chairman and will assist with leadership transition.
- Board has initiated a search for a permanent CEO; Giacobello's interim role ends when successor is appointed.

## SEC filing metadata
- accession: 0001193125-23-059077
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/d377824d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-059077
- JSON: https://secwatch.observer/filing/0001193125-23-059077.json
- Plain text: https://secwatch.observer/filing/0001193125-23-059077.txt

## Key facts
- Executive change
  Brendan Delaney resigned as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm
- Executive change
  Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer and President
  source text: Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.